Stryker Corporation (SYK) Stock Price & How to Invest

Stryker Corporation is a global medical technology company organized into two reportable segments: MedSurg and Neurotechnology (about 62% of 2025 sales) and Orthopaedics (about 38%). Its products include surgical instruments and navigation, endoscopy and communications systems, patient handling and emergency medical equipment, minimally invasive vascular and neurovascular devices, and orthopaedic implants for hips, knees, and trauma. The company's signature differentiator is Mako robotic-arm assisted surgery, which pulls hospitals into Stryker's ecosystem of implants and enabling technology; in early 2026 Stryker recast its Orthopaedics operations into a new Ortho Tech business that pairs orthopaedic instruments with Mako and enabling technologies.

The investment picture centers on Stryker's long track record of consistent organic growth, a diversified product base that reduces reliance on any single device line, and steady acquisitions that expand its reach. In 2025 net sales reached roughly $25.1 billion, up more than 11%, and management has guided full-year 2026 organic growth of 8.0% to 9.5%. At the start of 2026 management guided organic growth of 8.0% to 9.5%. The year has been bumpier than that framing suggested. Q1 2026 was dented by a late-quarter cyber incident and EPS of $2.60 missed the ~$2.98 consensus; Q2 recovered, with revenue of ~$6.59 billion (up about 9% year over year) and adjusted EPS of $3.69 against ~$3.49 expected. In September the CFO said supply constraints in peripheral vascular manufacturing would likely persist into Q4 and noted slower hip sales over the summer, and investors have also weighed a CEO transition, with Spencer Stiles named as incoming CEO. In October Stryker agreed to invest $400 million in CMR Surgical for exclusive U.S. rights to its Versius soft-tissue robot plus an option to buy the company, and won FDA clearance for its Sonopet 3 ultrasonic tissue-removal system. As of October 16, 2026 the stock closed near $294, down about 16% year to date, for a market cap near $113 billion and about 29x trailing and 18x forward earnings. The picture is one of a durable grower whose valuation has come down to meet a noisier year.

Stryker still trades at a premium to many medtech peers, so any further slowdown in organic growth or margin progress can pressure the multiple, even after the stock fell about 20% over the past year. Q1 2026 results were hurt by a late-quarter cyber incident that missed EPS estimates, and in September management flagged peripheral vascular supply constraints likely lasting into Q4 plus slower summer hip sales. A CEO transition adds leadership uncertainty, and the $400 million CMR Surgical investment, with an option to acquire, brings execution risk in a soft-tissue robotics market dominated by Intuitive Surgical. The company faces strong competition in robotics and implants from Zimmer Biomet, Johnson & Johnson, Medtronic, and Smith and Nephew, plus pricing pressure from hospitals and payers. Integration risk from frequent acquisitions, currency swings, debt of about $15.5 billion, and regulatory or reimbursement changes add further uncertainty. Elective-procedure volumes can also be sensitive to macro and hospital-capacity conditions.

26 analysts publish price targets on SYK, averaging $362.62 against a $294.66 price as of October 2026, or +23.1%. The published targets run from $298.00 to $465.00, a moderate spread, and the ratings split 23 buy, 6 hold, 0 sell. Over the last six months there have been 0 raises and 11 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SYK forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Stryker Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Mako robotics and enabling technology. Mako robotic-arm assisted surgery is Stryker's core moat, driving robotic knee and hip procedures and locking hospitals into its implant and instrument ecosystem. The most optimistic published target, $465.00, assumes this works close to its best case.

The case against. Stryker still trades at a premium to many medtech peers, so any further slowdown in organic growth or margin progress can pressure the multiple, even after the stock fell about 20% over the past year. The most pessimistic target, $298.00, is roughly what SYK is worth if this bites instead.

Read the full bull and bear case on SYK, including what would have to change to break either one. Walnut is not an investment adviser.

No. Stryker Corporation (SYK) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Stryker Corporation's investor relations page or your broker.

• Revenue (TTM): ~$25.8B (Q2 up ~9%)
• Q2 2026 adj. EPS: $3.69 vs ~$3.49 est.
• Net income (TTM): ~$3.7B
• Gross / operating margin: ~66% / ~27%
• Market cap: ~$113B
• P/E (trailing / forward): ~29x / ~18x
• Dividend yield: ~1.2%

Stryker closed near $294 on October 16, 2026, down about 16% this year, which has pulled its forward P/E to roughly 18x from about 22x in mid-2026. Q2 2026 beat estimates after a Q1 miss tied to the cyber incident, and trailing free cash flow is about $4.1 billion. Q3 results are due October 29, 2026, with consensus near $3.55 EPS on ~$6.6 billion of revenue.

Other names that sit close to SYK: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SYK exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SYK sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SYK fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

SYK is a high-quality medtech franchise that has de-rated in 2026, to about 18x forward earnings from roughly 22x in mid-year, after a cyber incident, supply issues and leadership change weighed on the shares. The debate is whether that discount is temporary noise or a slower-growth reset; the Q3 report on October 29, 2026 and early 2027 guidance are the next checkpoints.

Whether SYK is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SYK a buy or a sell?, and where the stock could go from here in the SYK stock forecast.

For income investors, whether SYK pays a dividend and how the payout looks is covered in does SYK pay a dividend? And to weigh SYK against a peer, read the full side-by-side comparisons: SYK vs ZBH and SYK vs MDT.